SPECIAL REPORT

Healthy Horizons
A brand new series of weekly segments which will explore the macro and micro issues facing the global economy.

LATEST FROM OUR BLOGS

» More

- 10 Dividend Picks For Your Portfolio: Chief Investors

MORE HEADLINES

» Markets | Economy | Companies

- Dubai Debt Delays Revive Fear of Financial Crisis

PHARMA'S MARKET VIDEO

» More

Sebelius on Vaccines

24 Nov 2009

Discussing whether a new $487M investment from the government will help speed up the production of the most important vaccines, with Kathy Sebelius, Health & Human Services secretary and CNBC's Mike Huckman.

The New Formula for Faster Vaccines

24 Nov 2009

Novartis is opening on Tuesday the country's first plant to produce flu vaccines using cell cultures. These vaccines are faster, better and cheaper to make than egg-based methods, reports CNBC's Mike Huckman.

Novartis Opens 1st US Plant for Flu Vaccine

24 Nov 2009

Cholesterol Drug Battle: Niaspan vs. Zetia 16 Nov 2009
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. CNBC's Mike Huckman has the details.

Cardiologist Grades Cholesterol Drug Study

16 Nov 2009

Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. Dr. Steven Nissen, chairman of the Department of Cardiovascular Medicine at The Cleveland Clinic, shares his reaction with CNBC's Mike Huckman.

Merck's Cholesterol Drugs Under Pressure

16 Nov 2009

A new study is putting Merck's cholesterol drugs under pressure today, reports CNBC's Mike Huckman, with Ken Frazier, Merck Global Human Health president.

RSS FEED

» Help

Subscribe to this RSS feed
Stay up to date with Pharma's Market.

CNBC ON DIGG

Pharma's Market

Text Size

May.12

10:23 AM ET

Tuesday, 12 May 2009

Carl Icahn Takes On Biogen Idec ... Again

Posted By:Mike Huckman

Topics:Medicine | Corporate News | Mergers & Acquisitions | Pharmaceuticals

Sectors:Health Care Equipment and Services | Health Care | Pharmaceuticals

Companies:Eli Lilly and Company | Amylin Pharmaceuticals | Biogen Idec Inc | Bristol-Myers Squibb Co

Carl Icahn
AP
Carl Icahn
Billionaire activist investor (It seems it's become almost de rigueur to put those three words before his name) Carl Icahn is apparently so busy waging a proxy fight against biotechs Amylin Pharmaceuticals and Biogen Idec that he hasn't posted a new blog entry in nearly a month.

I guess he's been spending a lot of his time penning proxy materials for AMLN [AMLN Loading... () ] and now BIIB [BIIB Loading... () ]. I mean, check out his 57-page tome for his latest attempt at forcing change at BIIB. He has tried and failed before to have his way with Biogen Idec.

But that isn't stopping him from giving it another go. Now, Icahn appears to be emboldened by his recent success with ImClone Systems, which he pushed into a sale to Eli Lilly [LLY Loading... () ] for six-and-a-half billion bucks. Eleven pages of Icahn's BIIB proxy materials are devoted to what he and his people claim they did for ImClone.

"Our (board) nominees helped deliver results at ImClone," the document says. And it goes on. "ImClone shares dramatically outperformed during new executive committee tenure. New executive committee enhanced value at ImClone. Recharged ImClone partner relations and optimized cost structure."

There he's referring to what was, by nearly all accounts, ImClone's fractured relationship with Bristol-Myers Squibb [BMY Loading... () ] . Wait, he's not finished. "Rebuilt pipeline, changed culture and settled litigation." Heck, why leave out "reinvented the wheel?" I'm kidding, Carl.

Anyway, Icahn concludes, "We believe ImClone and Biogen Idec situations analogous." Among his several proposals is a request for the board to look at splitting BIIB into two units: one focused on cancer, the other on neurology. BIIB's board has previously made its case to investors to tell Icahn to take a hike.

The Biogen Idec shareholder meeting is June 3rd, exactly one week after the Amylin meeting. The back-to-back battles should be a telling test of Icahn's influence.